Human LAIR1 / CD305 Protein, His Tag
Proteins and Peptides
- 貨號 Cat. No.
- CD5-H52H1
- 規格 Size
- 1mg
- 品牌 Brand
- ACROBiosystems
- Species
- Human
- Conjugate
- Unconjugated
- Expression System
- HEK293
- Tag
- His Tag
Description
Source :
Human LAIR-1, His Tag (CD5-H52H1) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - His 163 (Accession # Q6GTX8-1).
Molecule : LAIR-1
Synonyms : LAIR1,CD305
Format : Powder
Category : Immune Checkpoint Proteins
Accession : AAH27899.1
Storage : -20℃
Shipping condition : Powder,RT
Molecular Weight : 17.4 kDa
Characteristics :
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 17.4 kDa. The protein migrates as 26-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level : Less than 1.0 EU per μg by the LAL method.
Buffer : PBS, pH7.4
Description :
Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is constitutively expressed on the majority of human peripheral blood mononuclear leukocytes. LAIR-1 or CD305 is a transmembrane glycoprotein with a single immunoglobulin-like domain and a cytoplasmic tail containing two immune receptor tyrosine-based inhibitory motifs. LAIR-1 recruits SHP-1 and SHP-2 phosphatases upon activation, and cross-linking of the LAIR-1 antigen on natural killer (NK) cells results in strong inhibition of NK cell–mediated cytotoxicity.
Functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation.Diseases associated with LAIR1 include Chronic Active Epstein-Barr Virus Infection and Palindromic Rheumatism.
References :
(1) Pioli C, et all., 2000, J Immunol. 15;165(10):5530-6.
(2) Brondijk TH, et all., 2010, Blood. 18;115(7):1364-73
(3) Meyaard L, et all., 1997, Immunity. Aug;7(2):283-90.

